Moderna Surges as Healthcare Stock with Best Q1 Performance in S&P 500

The biotech company's transition from pandemic player to diversified pipeline could drive long-term growth.

Apr. 7, 2026 at 9:10am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, intricately designed banking and financial equipment in shades of steel gray, bronze, and chrome, conceptually representing the complex infrastructure supporting the growth of the healthcare and biotech industries.Moderna's transition from a pandemic player to a diversified biotech with a robust pipeline is reflected in the complex financial machinery powering its growth.Cambridge Today

Moderna, the biotech company known for its COVID-19 vaccine, delivered the best first-quarter performance among healthcare stocks in the S&P 500, surging 72%. This marks a shift in investor sentiment as Moderna transitions from a pandemic-focused company to one with a diversified pipeline spanning infectious diseases, oncology, and rare diseases.

Why it matters

Moderna's strong Q1 performance reflects a broader investor interest in healthcare stocks as a safe haven amid market volatility. The company's ability to leverage its COVID-19 vaccine revenue to fund the development of a broader pipeline could position it for long-term growth, beyond the pandemic era.

The details

Moderna's Q1 surge was driven by investors seeking stable, revenue-generating healthcare companies as concerns over AI and geopolitical tensions weighed on the market. The company has commercialized two COVID-19 vaccines and an RSV vaccine, and has submitted a flu candidate for regulatory review. Moderna expects its seasonal vaccine franchise to deliver up to 10% revenue growth this year, providing funding for its oncology and rare disease programs. The biotech has also reduced costs by 30% since 2024 and has over $8 billion in cash to support its pipeline development.

  • Moderna soared 72% in the first quarter of 2026.
  • The company expects revenue from its seasonal vaccine franchise to deliver up to 10% growth this year.

The players

Moderna

A biotech company known for developing the COVID-19 vaccine, which is now transitioning to a diversified pipeline spanning infectious diseases, oncology, and rare diseases.

Merck

A pharmaceutical giant that is collaborating with Moderna on the development of the mRNA-4157 oncology candidate, which is in phase 2 and phase 3 trials across multiple tumor types.

Got photos? Submit your photos here. ›

What’s next

Moderna may report phase 3 melanoma data for its mRNA-4157 oncology candidate this year, which could be a significant milestone if the results are positive.

The takeaway

Moderna's transition from a pandemic-focused company to one with a diversified pipeline spanning infectious diseases, oncology, and rare diseases has attracted renewed investor interest, as evidenced by its strong first-quarter performance. The company's ability to leverage its COVID-19 vaccine revenue to fund pipeline development could position it for long-term growth beyond the pandemic era.